Amicus Therapeutics Inc (FOLD)
11.00
+0.03
(+0.27%)
USD |
NASDAQ |
Nov 08, 16:00
11.00
0.00 (0.00%)
After-Hours: 20:00
Amicus Therapeutics Revenue (Annual): 399.36M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 399.36M |
December 31, 2022 | 329.23M |
December 31, 2021 | 305.51M |
December 31, 2020 | 260.89M |
December 31, 2019 | 182.24M |
December 31, 2018 | 91.24M |
December 31, 2017 | 36.93M |
December 31, 2016 | 4.958M |
December 31, 2015 |
Date | Value |
---|---|
December 31, 2014 | 1.224M |
December 31, 2013 | 0.363M |
December 31, 2012 | 18.41M |
December 31, 2011 | 21.43M |
December 31, 2010 | 0.922M |
December 31, 2009 | 64.36M |
December 31, 2008 | 14.97M |
December 31, 2007 | 1.784M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
182.24M
Minimum
2019
399.36M
Maximum
2023
295.45M
Average
305.51M
Median
2021
Revenue (Annual) Benchmarks
Tonix Pharmaceuticals Holding Corp | 7.768M |
Alnylam Pharmaceuticals Inc | 1.828B |
Krystal Biotech Inc | 50.70M |
Akero Therapeutics Inc | -- |
NovaBay Pharmaceuticals Inc | 14.73M |